Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 26

  • 1 201 clinical trials
  • 458 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia77Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Follicular lymphoma41Plasma cell myeloma refractory41Mantle cell lymphoma32Myelofibrosis31Chronic myeloid leukaemia29B-cell small lymphocytic lymphoma28Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17B-cell lymphoma refractory16B-cell type acute leukaemia16Paroxysmal nocturnal haemoglobinuria16Diffuse large B-cell lymphoma refractory14+340

Clinical trials in Blood and lymphatic system disorders

1 201 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 201 clinical trials

Acute myeloid leukaemia

Recruiting

Study on Fludarabine, Melphalan, and Radiation for Patients with High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Preparing for Stem Cell Transplant.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla

Plasma cell myeloma

Recruiting

Study on Imaging Multiple Myeloma Patients Using Fluciclovine (18F) PET/CT

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Fluciclovine (18F)
  • Sponsor:Oslo University Hospital HF

Sickle cell disease+1

Recruiting

Long-term safety study of oral etavopivat tablets in children, adolescents and adults with sickle cell disease or thalassaemia who completed previous etavopivat treatment

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Etavopivat
  • Sponsor:Novo Nordisk A/S

Acute lymphocytic leukaemia

Recruiting

Study of Ruxolitinib and Chemotherapy Drug Combination for Children with Acute Lymphoblastic Leukemia and JAK/STAT Pathway Activation

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Asparaginase
  • Sponsor:Medical University Of Lodz

Acute myeloid leukaemia

Recruiting

Study on Cyclophosphamide and Etoposide with Radiation for High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Patients Preparing for Transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla

Waldenstrom's macroglobulinaemia

Recruiting

Study on Venetoclax and Rituximab for Patients with Waldenström’s Macroglobulinemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Universitaetsklinikum Ulm AöR

Acute lymphocytic leukaemia

Recruiting

Study on CART 19/22 T Cells and CART45RA-NKG2D Cells for Treating Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents, and Young Adults

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Cart 19/22 T Cells
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz

Follicular lymphoma

Recruiting

Study on Early Stage Follicular Lymphoma: Evaluating Radiotherapy with Rituximab or Obinutuzumab for Patients with Early Stage Nodal Follicular Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Acute myeloid leukaemia+3

Recruiting

Study on Ponatinib for Treating Recurrent or Refractory Leukemias and Solid Tumors in Children

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Ponatinib
  • Sponsor:Incyte Biosciences International S.a.r.l.

Immune thrombocytopenia

Recruiting

Study Comparing Avatrombopag and Rituximab for Adults with Immune Thrombocytopenia Not Responding to Corticosteroids

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Avatrombopag
  • Sponsor:Ostfold Hospital Trust

Atypical haemolytic uraemic syndrome

Recruiting

Study on Switching from Anti-C5 Antibody Therapy to Iptacopan for Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

B-cell lymphoma+2

Recruiting

Long-Term Follow-Up Study for Patients Treated with CAR T-Cell Therapy Using PHE885, YTB323, and Tisagenlecleucel

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tisagenlecleucel
  • Sponsor:Novartis Pharma Services AG

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab122 clinical trialsVenetoclax114 clinical trialsCyclophosphamide100 clinical trialsLenalidomide98 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.